|
RASGEF1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.02030000010056E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.12279999975718E-07 |
| Normal-vs-Stage2 |
5.093800E-01 |
| Normal-vs-Stage3 |
1.48540000000086E-06 |
| Normal-vs-Stage4 |
1.368550E-04 |
| Stage1-vs-Stage2 |
6.102600E-03 |
| Stage1-vs-Stage3 |
7.043000E-01 |
| Stage1-vs-Stage4 |
6.214400E-01 |
| Stage2-vs-Stage3 |
2.378300E-03 |
| Stage2-vs-Stage4 |
7.101000E-03 |
| Stage3-vs-Stage4 |
8.117800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.76330003113179E-09 |
| Normal-vs-AfricanAmerican |
2.676300E-02 |
| Normal-vs-Asian |
8.648700E-04 |
| Caucasian-vs-AfricanAmerican |
4.336000E-01 |
| Caucasian-vs-Asian |
4.338200E-01 |
| AfricanAmerican-vs-Asian |
8.381200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.29549999999957E-05 |
| Normal-vs-Female |
4.26499999983676E-07 |
| Male-vs-Female |
8.174600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.99380000076977E-08 |
| Normal-vs-Age(41-60Yrs) |
3.83219999999795E-05 |
| Normal-vs-Age(61-80Yrs) |
5.655200E-03 |
| Normal-vs-Age(81-100Yrs) |
1.599030E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.116300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.096190E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.712800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.701200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.549400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.424200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.168300E-02 |
| Classical-VS-Follicular |
1.62436730732907E-12 |
| Classical-VS-Other |
5.889600E-01 |
| Classical-VS-Normal |
1.61289981370771E-10 |
| Tall-VS-Follicular |
<1E-12 |
| Tall-VS-Other |
1.004410E-01 |
| Tall-VS-Normal |
2.77399991865934E-10 |
| Follicular-VS-Other |
7.437600E-02 |
| Follicular-VS-Normal |
2.987600E-02 |
| Other-VS-Normal |
2.004400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.448020E-02 |
| Normal-vs-N1 |
3.756100E-04 |
| N0-vs-N1 |
3.394400E-02 |
|
|
